文献速递前列腺癌

患者与疾病特征与2010至2016年低危前列腺癌过度治疗的相关性

The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-03-30

该研究基于美国国家癌症数据库(NCDB)2010至2016年数据,纳入36,088例接受根治性前列腺切除术(RP)的低危前列腺癌男性(45-75岁,cT1 cN0 cM0,活检Gleason评分6,PSA<10 ng/ml),采用多变量逻辑回归分析基线特征与RP后临床无意义前列腺癌(iPCa,即过度治疗)的关联。结果显示iPCa未调整率从2010年54.7%降至2016年40.0%,研究期间过度治疗率降低约27%;较年长、较晚诊断年份、黑人种族、学术/研究机构治疗、较高PSA及较多阳性穿刺针数与iPCa风险降低独立相关,而较多穿刺取样针数与iPCa风险升高独立相关。

要点

  • 研究期间低危前列腺癌RP后iPCa未调整率从2010年54.7%降至2016年40.0%,过度治疗率降低约27%。
  • 较年长、较晚诊断年份、黑人种族、学术/研究机构治疗、较高PSA及较多阳性穿刺针数与iPCa风险降低独立相关。
  • 较多活检取样针数与iPCa风险升高独立相关(OR 1.01,95%CI 1.01-1.02)。

核心结论

  • 研究期间低危前列腺癌男性过度治疗率降低约27%,若干患者、疾病及结构特征与RP后iPCa检出相关,可为低危前列腺癌管理提供信息以减少潜在过度治疗。

研究设计与样本

  • 回顾性分析美国国家癌症数据库(NCDB)2010至2016年数据,纳入45-75岁、cT1 cN0 cM0、活检Gleason评分6且PSA<10 ng/ml并接受根治性前列腺切除术(RP)的前列腺腺癌男性36,088例。
  • 采用多变量逻辑回归评估基线特征与RP后临床无意义前列腺癌(iPCa,定义为器官局限即pT2、Gleason 3+3疾病)的关联。

主要发现

  • iPCa未调整率从2010年54.7%降至2016年40.0%。
  • 多变量分析中,较年长(OR 0.98,95%CI 0.97-0.98)、较晚诊断年份(2016年 vs 2010年,OR 0.62,95%CI 0.57-0.67)、黑人种族(OR 0.85,95%CI 0.79-0.91)、学术/研究机构治疗(OR 0.82,95%CI 0.73-0.91)、较高PSA(OR 0.91,95%CI 0.90-0.92)及较多阳性穿刺针数(OR 0.87,95%CI 0.86-0.88)与RP后iPCa风险降低独立相关。
  • 较多活检取样针数(OR 1.01,95%CI 1.01-1.02)与RP后iPCa风险升高独立相关。

临床怎么用

  • 作者认为,若干患者、疾病及结构特征与RP后iPCa检出相关,可为低危前列腺癌男性管理提供信息以减少潜在过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although active surveillance is the preferred management for low-risk prostate cancer (PCa), some men remain at risk of overtreatment with definitive local therapy. We hypothesized that baseline characteristics may be associated with overtreatment and represent a potential source of health disparities. We therefore examined the associations of patient and disease characteristics with the surgical overtreatment of low-risk PCa. METHODS: We identified men aged 45-75 years with cT1 cN0 cM0 prostate adenocarcinoma with biopsy Gleason score 6 and PSA < 10 ng/ml from 2010-2016 in the National Cancer Database (NCDB) and who underwent radical prostatectomy (RP). We evaluated the associations of baseline characteristics with clinically insignificant PCa (iPCa) at RP (i.e., "overtreatment"), defined as organ-confined (i.e., pT2) Gleason 3 + 3 disease, using multivariable logistic regression. RESULTS: We identified 36,088 men with low-risk PCa who underwent RP. The unadjusted rate of iPCa decreased during the study period, from 54.7% in 2010 to 40.0% in 2016. In multivariable analyses adjusting for baseline characteristics, older age (OR 0.98, 95% CI 0.97-0.98), later year of diagnosis (OR 0.62, 95% CI 0.57-0.67 for 2016 vs. 2010), Black race (OR 0.85, 95% CI 0.79-0.91), treatment at an academic/research program (OR 0.82, 95% CI 0.73-0.91), higher PSA (OR 0.91, 95% CI 0.90-0.92), and higher number of positive biopsy cores (OR 0.87, 95% CI 0.86-0.88) were independently associated with a lower risk of overtreatment (iPCa) at RP. Conversely, a greater number of biopsy cores sampled (OR 1.01, 95% CI 1.01-1.02) was independently associated with an increased risk of overtreatment (iPCa) at RP. CONCLUSIONS: We observed an ~27% reduction in rates of overtreatment of men with low-risk PCa over the study period. Several patient, disease, and structural characteristics are associated with detection of iPCa at RP and can inform the management of men with low-risk PCa to reduce potential overtreatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Desmond C, Kaul S, Fleishman A, et al. The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. Prostate Cancer Prostatic Dis. 2024. PMID: 38555410. doi:10.1038/s41391-024-00822-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。